References

Diagnosis and classification of diabetes: standards of care in diabetes-2025

10.2337/dc25-s002 · 2025 · External reference

Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus

10.1161/circulationaha.110.014506 · 2011 · External reference

Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis

10.1161/circulationaha.120.046464 · 2021 · External reference

Activator protein-1 (AP-1) inhibition prevents endothelial to mesenchymal transition in diabetes-associated atherosclerosis: a translational study

10.1186/s12933-025-03060-5 · 2026 · External reference

Hyperglycemia, duration of diabetes, and intracranial atherosclerotic stenosis by magnetic resonance angiography: the ARIC-NCS study

10.1016/j.jdiacomp.2020.107605 · 2020 · External reference

Long-term risk of cardiovascular disease among type 2 diabetic patients with asymptomatic intracranial atherosclerosis: a prospective cohort study

10.1371/journal.pone.0106623 · 2014 · External reference

Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention

10.1038/s41569-023-00877-z · 2023 · External reference

2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association

10.1161/cir.0000000000001303 · 2025 · External reference

Glucose-6-phosphate dehydrogenase deficiency and intracranial atherosclerotic stenosis in stroke patients

10.1111/ene.15418 · 2022 · External reference

Optimal medical management of atherosclerotic intracranial stenosis

10.1161/strokeaha.123.043633 · 2024 · External reference

Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment

10.1016/s1474-4422(21)00376-8 · 2022 · External reference

Determinants and outcomes of asymptomatic intracranial atherosclerotic stenosis

10.1016/j.jacc.2021.05.041 · 2021 · External reference

Chinese guidelines for diagnosis and treatment of intracranial atherosclerotic stenosis

10.1177/17474930261419812 · 2026 · External reference

Intracranial atherosclerotic stenosis in Asia: a systematic scoping and rapid review of prevalence, frequency in ischaemic stroke and risk factors

10.1136/bmjno-2025-001164 · 2025 · External reference

Intracranial arterial stenosis in Caucasian versus Chinese patients with TIA and minor stroke: two contemporaneous cohorts and a systematic review

10.1136/jnnp-2020-325630 · 2021 · External reference

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

10.1016/s0140-6736(23)00215-5 · 2023 · External reference

Fibroblast growth factor 21 in metabolic syndrome

10.3389/fendo.2023.1220426 · 2023 · External reference

Total serum FGF-21 levels positively relate to visceral adiposity differently from its functional intact form

10.3389/fendo.2023.1159127 · 2023 · External reference

Berberine protects mice against type 2 diabetes by promoting PPARgamma-FGF21-GLUT2-regulated insulin sensitivity and glucose/lipid homeostasis

10.1016/j.bcp.2023.115928 · 2023 · External reference

Prolonged FGF21 treatment increases energy expenditure and induces weight loss in obese mice independently of UCP1 and adrenergic signaling

10.1016/j.bcp.2024.116042 · 2024 · External reference

FGF21 overexpression alleviates VSMC senescence in diabetic mice by modulating the SYK-NLRP3 inflammasome-PPARgamma-catalase pathway

10.3724/abbs.2024032 · 2024 · External reference

Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice

10.1038/s41374-021-00680-9 · 2022 · External reference

Fibroblast growth factor 21 resistance is associated with body shape in patients with type 2 diabetes complicating hypertension

10.3389/fcvm.2023.1168047 · 2023 · External reference

ADAM10-mediated beta-klotho degradation: a key to FGF21 resistance in senescent vascular endothelial cells

10.1007/s11357-024-01463-y · 2025 · External reference

Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans

10.2337/db07-1476 · 2008 · External reference

Relationship between serum FGF21 and vWF expression and carotid atherosclerosis in elderly patients with hypertension

10.1155/2022/6777771 · 2022 · External reference

The roles of FGF21 in atherosclerosis pathogenesis

10.1007/s11154-019-09488-x · 2019 · External reference

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

10.7150/ijbs.73936 · 2023 · External reference

Fibroblast growth factor 21 and prognosis of patients with cardiovascular disease: a meta-analysis

10.3389/fendo.2023.1108234 · 2023 · External reference

The correlation between serum fibroblast growth factor 21 and the severity and occurrence of coronary artery disease

10.7759/cureus.51924 · 2024 · External reference

Increased circulating FGF21 level predicts the burden of metabolic demands and risk of vascular diseases in adults with type 2 diabetes

10.1186/s12902-023-01523-y · 2023 · External reference

A standardized method for measuring intracranial arterial stenosis

2000 · External reference

Medical management and revascularization for asymptomatic carotid stenosis

10.1056/nejmoa2508800 · 2026 · External reference

European stroke organisation guidelines on treatment of patients with intracranial atherosclerotic disease

10.1177/23969873221099715 · 2022 · External reference

Concomitant diabetes or hypertension with metabolic syndrome on the extent of intracranial atherosclerotic stenosis

10.1007/s10072-019-04105-w · 2020 · External reference

Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors

10.1161/atvbaha.113.301599 · 2013 · External reference

Association between serum fibroblast growth factor 21 and coronary artery disease in patients with type 2 diabetes

10.3346/jkms.2015.30.5.586 · 2015 · External reference

Fibroblast growth factor 21 promotes vascular smooth muscle cell contractile polarization via p38 mitogen-activated protein kinase-promoted serum response factor phosphorylation

10.34133/research.0815 · 2025 · External reference

Circulating markers of inflammation and endothelial dysfunction associated with increased progression of internal carotid intima-media thickness in the population-based Framingham heart study

10.1161/jaha.124.040460 · 2025 · External reference

Fibroblast growth factor 21 protects against high glucose induced cellular damage and dysfunction of endothelial nitric-oxide synthase in endothelial cells

10.1159/000363031 · 2014 · External reference

Fibroblast growth factor 21 ameliorates diabetes-induced endothelial dysfunction in mouse aorta via activation of the CaMKK2/AMPKalpha signaling pathway

10.1038/s41419-019-1893-6 · 2019 · External reference

FGF21 alleviates diabetic vasculopathy with NF-kappaB suppression and fibrinolytic activation

10.1016/j.ejphar.2025.178224 · 2025 · External reference

Fibroblast growth factor 21 protects against cerebral ischemia/reperfusion injury by inhibiting oxidative stress and Ferroptosis

10.2147/ndt.s504180 · 2025 · External reference

The association between fibroblast growth factor 21 with diabetes retinopathy among type 2 diabetes mellitus patients: a systematic review, meta-analysis, and meta-regression

10.7717/peerj.18308 · 2024 · External reference